Mylan (NASDAQ:MYL)‘s stock had its “buy” rating reaffirmed by investment analysts at Citigroup in a note issued to investors on Thursday. They currently have a $58.00 price objective on the stock, up from their previous price objective of $48.00. Citigroup’s target price would indicate a potential upside of 34.45% from the company’s previous close.

Several other research analysts also recently commented on the company. Leerink Swann began coverage on Mylan in a research note on Tuesday. They set a “market perform” rating and a $44.00 target price for the company. Cantor Fitzgerald set a $41.00 price objective on Mylan and gave the company a “hold” rating in a research note on Tuesday, December 26th. BidaskClub raised Mylan from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 19th. Guggenheim started coverage on shares of Mylan in a research report on Tuesday, December 12th. They set a “buy” rating and a $59.00 target price for the company. Finally, UBS Group set a $46.00 target price on shares of Mylan and gave the company a “buy” rating in a research report on Monday, December 4th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $43.20.

Mylan (NASDAQ:MYL) traded up $0.03 on Thursday, reaching $43.14. 6,735,500 shares of the company traded hands, compared to its average volume of 6,744,200. Mylan has a 1-year low of $29.39 and a 1-year high of $45.87. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The company has a market capitalization of $23,140.00, a PE ratio of 25.99, a price-to-earnings-growth ratio of 2.77 and a beta of 1.38.

Mylan (NASDAQ:MYL) last posted its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. During the same period in the prior year, the company earned $1.38 EPS. The company’s revenue for the quarter was down 2.3% compared to the same quarter last year. sell-side analysts anticipate that Mylan will post 4.56 EPS for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the business. Meeder Asset Management Inc. boosted its position in shares of Mylan by 76.9% during the 3rd quarter. Meeder Asset Management Inc. now owns 3,393 shares of the company’s stock valued at $106,000 after acquiring an additional 1,475 shares during the last quarter. BT Investment Management Ltd bought a new stake in shares of Mylan during the 3rd quarter valued at about $142,000. Doliver Capital Advisors LP bought a new stake in shares of Mylan during the 2nd quarter valued at about $201,000. Sheaff Brock Investment Advisors LLC bought a new stake in shares of Mylan during the 2nd quarter valued at about $210,000. Finally, Loews Corp bought a new stake in Mylan in the 2nd quarter worth approximately $223,000. 74.90% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/04/mylan-myl-pt-raised-to-58-00.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.